Janux Therapeutics, Inc.
JANX
$23.35
-$0.29-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 439.00K | 9.34M | 10.59M | 13.05M | 15.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 439.00K | 9.34M | 10.59M | 13.05M | 15.13M |
| Cost of Revenue | 64.48M | 64.48M | 53.49M | 44.93M | 38.20M |
| Gross Profit | -64.04M | -55.14M | -42.90M | -31.88M | -23.08M |
| SG&A Expenses | 46.18M | 43.55M | 41.05M | 39.19M | 27.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 145.32M | 122.92M | 109.44M | 99.01M | 81.06M |
| Operating Income | -144.88M | -113.58M | -98.85M | -85.96M | -65.93M |
| Income Before Tax | -105.64M | -77.74M | -68.99M | -60.54M | -44.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.64 | -77.74 | -68.99 | -60.54 | -44.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.64M | -77.74M | -68.99M | -60.54M | -44.05M |
| EBIT | -144.88M | -113.58M | -98.85M | -85.96M | -65.93M |
| EBITDA | -142.80M | -111.54M | -96.79M | -83.88M | -63.86M |
| EPS Basic | -1.80 | -1.36 | -1.28 | -1.18 | -0.92 |
| Normalized Basic EPS | -1.12 | -0.85 | -0.80 | -0.73 | -0.57 |
| EPS Diluted | -1.80 | -1.36 | -1.28 | -1.18 | -0.92 |
| Normalized Diluted EPS | -1.12 | -0.85 | -0.80 | -0.73 | -0.57 |
| Average Basic Shares Outstanding | 235.16M | 227.70M | 214.96M | 204.81M | 195.89M |
| Average Diluted Shares Outstanding | 235.16M | 227.70M | 214.96M | 204.81M | 195.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |